[go: up one dir, main page]

WO2009008901A3 - Peptide and small molecule agonises of epa and their uses in diseases - Google Patents

Peptide and small molecule agonises of epa and their uses in diseases Download PDF

Info

Publication number
WO2009008901A3
WO2009008901A3 PCT/US2007/087613 US2007087613W WO2009008901A3 WO 2009008901 A3 WO2009008901 A3 WO 2009008901A3 US 2007087613 W US2007087613 W US 2007087613W WO 2009008901 A3 WO2009008901 A3 WO 2009008901A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonises
epa
peptide
diseases
small molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/087613
Other languages
French (fr)
Other versions
WO2009008901A2 (en
Inventor
Bingcheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Priority to US12/519,294 priority Critical patent/US20100093626A1/en
Publication of WO2009008901A2 publication Critical patent/WO2009008901A2/en
Publication of WO2009008901A3 publication Critical patent/WO2009008901A3/en
Anticipated expiration legal-status Critical
Priority to US15/244,784 priority patent/US20170165322A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a neoplastic disorder in a subject includes administering to a Eph kinase expressing neoplastic cell of the subject being treated an EphA agonist and at least one immunosuppressant.
PCT/US2007/087613 2006-12-15 2007-12-14 Peptide and small molecule agonises of epa and their uses in diseases Ceased WO2009008901A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/519,294 US20100093626A1 (en) 2006-12-15 2007-12-14 Peptide and small molecule agonists of epha and their uses in disease
US15/244,784 US20170165322A1 (en) 2006-12-15 2016-08-23 Peptide and small molecule agonists of epha and their uses in disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87509606P 2006-12-15 2006-12-15
US60/875,096 2006-12-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/519,294 A-371-Of-International US20100093626A1 (en) 2006-12-15 2007-12-14 Peptide and small molecule agonists of epha and their uses in disease
US15/244,784 Continuation US20170165322A1 (en) 2006-12-15 2016-08-23 Peptide and small molecule agonists of epha and their uses in disease

Publications (2)

Publication Number Publication Date
WO2009008901A2 WO2009008901A2 (en) 2009-01-15
WO2009008901A3 true WO2009008901A3 (en) 2009-03-12

Family

ID=40229306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087613 Ceased WO2009008901A2 (en) 2006-12-15 2007-12-14 Peptide and small molecule agonises of epa and their uses in diseases

Country Status (2)

Country Link
US (2) US20100093626A1 (en)
WO (1) WO2009008901A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2199390T3 (en) 2007-08-30 2017-06-30 Daiichi Sankyo Company, Limited Anti-epha2 antibody
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011057251A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US11814372B2 (en) 2017-07-03 2023-11-14 Case Western Reserve University Agonists of EPHA and their uses
US11944624B2 (en) 2017-07-06 2024-04-02 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
CN117511855B (en) * 2023-11-09 2024-11-19 南京医科大学 Use of EPHA inhibitors for inducing meiosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136983A1 (en) * 1998-11-20 2004-07-15 Michel Aguet Methods for inhibiting angiogenesis by EphB receptor antagonists
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136983A1 (en) * 1998-11-20 2004-07-15 Michel Aguet Methods for inhibiting angiogenesis by EphB receptor antagonists
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
WO2009008901A2 (en) 2009-01-15
US20170165322A1 (en) 2017-06-15
US20100093626A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2009008901A3 (en) Peptide and small molecule agonises of epa and their uses in diseases
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2006104913A3 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
IL190613A0 (en) Iv catheter with in-line valve and methods related thereto
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2008070135A3 (en) Methods of treating systemic lupus erythematosus
WO2007030642A3 (en) Toxin conjugated eph receptor antibodies
WO2009109911A8 (en) Methods of treating chronic pain
WO2006076651A3 (en) Treatment method
PL1833423T3 (en) Preloaded iol injector and method
CA120399S (en) Boot
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
MX348735B (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-a RECEPTOR.
WO2007143086A3 (en) Delivery method
IL185690A0 (en) Method for treating prostate diseases based on local delivery of active substances
WO2009155556A3 (en) Crkl targeting peptides
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2009050267A3 (en) Il24 for inducing hyperproliferative or autoimmune cell death
AU2007267997A8 (en) Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
WO2007133828A3 (en) Selective vpac2 receptor peptide agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874364

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12519294

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874364

Country of ref document: EP

Kind code of ref document: A2